ATAI Life Sciences BV (ATAI.US) Price Target 2026/2027: 35% Upside – Rating and Stock Analysis
ATAI Life Sciences BV Price Target 2026: Analysts See 33% Upside
The average price target for ATAI Life Sciences BV is $9.59. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 33,01% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.Is ATAI Life Sciences BV overvalued or undervalued?
ATAI Life Sciences BV is currently undervalued with a gap of 33% relative to the price target.
The current price is $7.21, which places ATAI Life Sciences BV in the undervalued category. The stock is considered undervalued when the price is below $8.63, and overvalued when the price exceeds $10.55.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For ATAI Life Sciences BV, the fair value range lies between $8.63 and $10.55.
See the full price target analysis for ATAI Life Sciences BV →
Analyst Ratings for ATAI Life Sciences BV stock in 2026: Strong Buy
7 analysts cover ATAI Life Sciences BV. There is broad agreement on a positive view — 100% recommend buying. The average price target is $9.59, which gives an upside of 33% from the current price.
About ATAI Life Sciences BV – Bioteknologi
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. Read more about the companyKey Figures for ATAI Life Sciences BV
What kind of stock is ATAI Life Sciences BV?
ATAI Life Sciences BV is classified as a momentum stock with a momentum score in the top 1% of all stocks. The price has risen 0.0% over the long term.
Score Overview for ATAI Life Sciences BV
📈 Valuation
The P/S ratio is 761.5 (high — the market pays a premium for the revenue). The P/B ratio is 13.4.
💵 Profitability & Growth
The latest quarterly earnings grew -96.8% year over year — falling earnings.
🏦 Financial Health
The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is -25.20 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 36.8% — low debt, a solid balance sheet.
🚀 Momentum & Short Interest
Short interest is 12.05% — very high, the market is skeptical.
ATAI Life Sciences BV Short Selling 2026: 12.1% Sold Short
What does this mean for you as an investor?
A short interest of 12.1% means that 12.1% of the freely traded shares in ATAI Life Sciences BV have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.
The next potential catalyst is the earnings report on 8/13/2026. With a short interest of 12.1%, the report can trigger considerable volatility.
Data is updated daily based on official filings with the SEC.
When Does ATAI Life Sciences BV Report Earnings – Next Date: 8/13/2026
The next earnings report from ATAI Life Sciences BV is scheduled for August 13, 2026, before the market opens. This report covers the second quarter (Q2), which ended on June 30, 2026.Technical Analysis of ATAI Life Sciences BV 2026 – Signal: Strong Buy
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.
Trend Analysis of ATAI Life Sciences BV
ATAI Life Sciences BV is in a short-term uptrend. The price of $7.22 is 7.6% above the 20-day average ($6.71). Medium term, the picture is positive: the price is 34.8% above the 50-day average ($5.36). Long term, the stock is 62.9% above the 200-day average ($4.43), which confirms a long-term uptrend.
Golden Cross: The 50-day average (5.36) is above the 200-day average (4.43), which is a classic bullish signal for ATAI Life Sciences BV.
Is ATAI Life Sciences BV overbought or oversold?
ATAI Life Sciences BV has an RSI of 74.3, which places the stock in overbought territory (above 70). Even though the stock is overbought, the broader trend is positive. A short-term pullback is possible, but the trend still supports the price.
MACD Analysis for ATAI Life Sciences BV
Daily MACD: MACD is positive (0.576), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is below the signal line (0.627) by 0.051, which suggests the positive momentum is fading – the trend could be turning.
Weekly MACD: MACD5 is positive (0.695), which indicates a broader bullish long-term trend. MACD5 is above the signal line (0.317) by 0.378, which confirms rising long-term momentum.
Overall MACD assessment: Both the daily and weekly trend are bullish (MACD positive). However, momentum shows signs of weakening on a daily basis. Watch whether the trend holds.
Risk Profile for ATAI Life Sciences BV
ATAI Life Sciences BV has an annual standard deviation of 80.7%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.
Overall Technical Conclusion for ATAI Life Sciences BV
Trend: Positive. The price trades above SMA50 and SMA200.
MACD trend (zero line): Daily bullish (0.576). Weekly bullish (0.695).
MACD momentum (signal): Daily falling. Weekly rising.
RSI: 74.3 – overbought.
Technical signal: Strong Buy
The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.